Roundview Capital LLC decreased its holdings in Abbott Laboratories (NYSE:ABT – Get Rating) by 8.3% in the 4th quarter, HoldingsChannel reports. The fund owned 15,695 shares of the healthcare product maker’s stock after selling 1,413 shares during the quarter. Roundview Capital LLC’s holdings in Abbott Laboratories were worth $2,209,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in ABT. Jackson Wealth Management LLC raised its position in Abbott Laboratories by 2.1% in the third quarter. Jackson Wealth Management LLC now owns 34,368 shares of the healthcare product maker’s stock worth $25,000 after acquiring an additional 722 shares in the last quarter. Blue Bell Private Wealth Management LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at $30,000. Retirement Group LLC increased its position in shares of Abbott Laboratories by 1,125.0% in the fourth quarter. Retirement Group LLC now owns 245 shares of the healthcare product maker’s stock valued at $34,000 after buying an additional 225 shares in the last quarter. Consolidated Planning Corp purchased a new position in shares of Abbott Laboratories in the third quarter valued at $36,000. Finally, Lumature Wealth Partners LLC increased its position in shares of Abbott Laboratories by 65.4% in the fourth quarter. Lumature Wealth Partners LLC now owns 301 shares of the healthcare product maker’s stock valued at $42,000 after buying an additional 119 shares in the last quarter. Hedge funds and other institutional investors own 73.46% of the company’s stock.
NYSE:ABT traded up $1.91 during mid-day trading on Friday, reaching $109.88. The company’s stock had a trading volume of 6,159,308 shares, compared to its average volume of 5,167,185. The company’s fifty day simple moving average is $117.37 and its two-hundred day simple moving average is $124.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.40. Abbott Laboratories has a twelve month low of $104.63 and a twelve month high of $142.60. The stock has a market cap of $192.39 billion, a P/E ratio of 25.49, a P/E/G ratio of 2.81 and a beta of 0.73.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 16th. Stockholders of record on Friday, April 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Wednesday, April 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.71%. Abbott Laboratories’s dividend payout ratio (DPR) is 43.62%.
In related news, SVP Julie L. Tyler sold 462 shares of the firm’s stock in a transaction dated Tuesday, February 22nd. The stock was sold at an average price of $119.29, for a total transaction of $55,111.98. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Daniel J. Starks sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of $113.22, for a total value of $5,661,000.00. Following the sale, the director now owns 6,973,500 shares in the company, valued at $789,539,670. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,896 shares of company stock worth $9,299,454. Company insiders own 0.52% of the company’s stock.
ABT has been the subject of a number of research analyst reports. Bank of America initiated coverage on Abbott Laboratories in a research report on Tuesday, March 1st. They issued a “buy” rating and a $140.00 price target for the company. Wells Fargo & Company decreased their price objective on Abbott Laboratories from $155.00 to $150.00 and set an “overweight” rating on the stock in a research note on Friday, April 8th. StockNews.com started coverage on Abbott Laboratories in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Royal Bank of Canada decreased their price objective on Abbott Laboratories from $146.00 to $143.00 and set an “outperform” rating on the stock in a research note on Thursday, April 21st. Finally, Morgan Stanley decreased their price objective on Abbott Laboratories from $157.00 to $151.00 and set an “overweight” rating on the stock in a research note on Thursday, January 27th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $138.83.
Abbott Laboratories Company Profile (Get Rating)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
- Get a free copy of the StockNews.com research report on Abbott Laboratories (ABT)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.